Advanced search
Start date
Betweenand
(Reference retrieved automatically from SciELO through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Myxovirus resistance, osteopontin and suppressor of cytokine signaling 3 polymorphisms predict hepatitis C virus therapy response in an admixed patient population: comparison with IL28B

Full text
Author(s):
Ana Luiza Dias Angelo [1] ; Lourianne Nascimento Cavalcante [2, 3] ; Kiyoko Abe-Sandes [1, 4] ; Taisa Bonfim Machado [1] ; Denise Carneiro Lemaire [1, 4] ; Fernanda Malta [5] ; Joao Renato Pinho [5] ; Luiz Guilherme Costa Lyra [3] ; Andre Castro Lyra [2, 5]
Total Authors: 9
Affiliation:
[1] Univ Fed Bahia, Immunol Lab, Salvador, BA - Brazil
[2] Univ Fed Bahia, Div Gastroenterol & Hepatol, Dept Med, Salvador, BA - Brazil
[3] Hosp Sao Rafael, Gastrohepatol Serv, Salvador, BA - Brazil
[4] Univ Estado Bahia, Dept Life Sci, Salvador, BA - Brazil
[5] Univ Sao Paulo, Fac Med, Lab Gastroenterol & Hepatol Trop, Sao Paulo - Brazil
Total Affiliations: 5
Document type: Journal article
Source: Clinics; v. 68, n. 10, p. 1325-1332, 2013-10-00.
Abstract

OBJECTIVES: Suppressor of cytokine signaling 3, myxovirus resistance protein and osteopontin gene polymorphisms may influence the therapeutic response in patients with chronic hepatitis C, and an association with IL28 might increase the power to predict sustained virologic response. Our aims were to evaluate the association between myxovirus resistance protein, osteopontin and suppressor of cytokine signaling 3 gene polymorphisms in combination with IL28B and to assess the therapy response in hepatitis C patients treated with pegylated-interferon plus ribavirin. METHOD: Myxovirus resistance protein, osteopontin, suppressor of cytokine signaling 3 and IL28B polymorphisms were analyzed by PCR-restriction fragment length polymorphism, direct sequencing and real-time PCR. Ancestry was determined using genetic markers. RESULTS: We analyzed 181 individuals, including 52 who were sustained virologic responders. The protective genotype frequencies among the sustained virologic response group were as follows: the G/G suppressor of cytokine signaling 3 (rs4969170) (62.2%); T/T osteopontin (rs2853744) (60%); T/T osteopontin (rs11730582) (64.3%); and the G/T myxovirus resistance protein (rs2071430) genotype (54%). The patients who had ≥3 of the protective genotypes from the myxovirus resistance protein, the suppressor of cytokine signaling 3 and osteopontin had a greater than 90% probability of achieving a sustained response (p<0.0001). The C/C IL28B genotype was present in 58.8% of the subjects in this group. The sustained virological response rates increased to 85.7% and 91.7% by analyzing C/C IL28B with the T/T osteopontin genotype at rs11730582 and the G/G suppressor of cytokine signaling 3 genotype, respectively. Genetic ancestry analysis revealed an admixed population. CONCLUSION: Hepatitis C genotype 1 patients who were responders to interferon-based therapy had a high frequency of multiple protective polymorphisms in the myxovirus resistance protein, osteopontin and suppressor of cytokine signaling 3 genes. The combined analysis of the suppressor of cytokine signaling 3 and IL28B genotypes more effectively predicted sustained virologic response than IL28B analysis alone. (AU)

FAPESP's process: 10/10549-1 - IL-28 gene single nucleotide polymorphisms (SNPs) genotyping in individuals infected with Hepatitis C virus
Grantee:João Renato Rebello Pinho
Support type: Regular Research Grants